

Confalonieri Paolo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1451726/publications.pdf>

Version: 2024-02-01

111
papers

3,666
citations

126858

33
h-index

149623

56
g-index

118
all docs

118
docs citations

118
times ranked

4184
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence and patterns of subclinical motor and cognitive impairments in non-disabled individuals with early multiple sclerosis: A multicenter cross-sectional study. <i>Annals of Physical and Rehabilitation Medicine</i> , 2022, 65, 101491.	1.1	11
2	A group resilience training program for people with multiple sclerosis: Study protocol of a multi-centre cluster-randomized controlled trial (multi-READY for MS). <i>PLoS ONE</i> , 2022, 17, e0267245.	1.1	3
3	Physical activity in non-disabled people with early multiple sclerosis: A multicenter cross-sectional study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 64, 103941.	0.9	5
4	The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The <i>ImpACT-COVID-19</i> for Patients <i>Multi-Centre Observational Study</i> . <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 340.	1.2	14
5	Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register. <i>Neurotherapeutics</i> , 2021, 18, 905-919.	2.1	9
6	Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups. <i>Frontiers in Immunology</i> , 2021, 12, 633167.	2.2	11
7	Living with severe multiple sclerosis: Cost-effectiveness of a palliative care intervention and cost of illness study. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102756.	0.9	2
8	Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing/Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study). <i>Frontiers in Neurology</i> , 2021, 12, 637615.	1.1	1
9	Neuro-telehealth for fragile patients in a tertiary referral neurological institute during the COVID-19 pandemic in Milan, Lombardy. <i>Neurological Sciences</i> , 2021, 42, 2637-2644.	0.9	18
10	Instrumentally assessed gait quality is more relevant than gait endurance and velocity to explain patient-reported walking ability in early-stage multiple sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 2259-2268.	1.7	11
11	Viability of a MSQOL-54 general health-related quality of life score using bifactor model. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 224.	1.0	2
12	Walking With Horizontal Head Turns Is Impaired in Persons With Early-Stage Multiple Sclerosis Showing Normal Locomotion. <i>Frontiers in Neurology</i> , 2021, 12, 821640.	1.1	5
13	Assessing measurement invariance of MSQOL-54 across Italian and English versions. <i>Quality of Life Research</i> , 2020, 29, 783-791.	1.5	4
14	Effects of Venous Angioplasty on Cerebral Lesions in Multiple Sclerosis: Expanded Analysis of the Brave Dreams Double-Blind, Sham-Controlled Randomized Trial. <i>Journal of Endovascular Therapy</i> , 2020, 27, 9-17.	0.8	18
15	Severe thrombocytopenia during Natalizumab therapy: A case report. <i>Journal of the Neurological Sciences</i> , 2020, 409, 116587.	0.3	2
16	Local Dynamic Stability of Gait in People With Early Multiple Sclerosis and No-to-Mild Neurological Impairment. <i>IEEE Transactions on Neural Systems and Rehabilitation Engineering</i> , 2020, 28, 1389-1396.	2.7	19
17	The IN-DEEP project <i>Integrating and Deriving Evidence, Experiences, Preferences</i> : a web information model on magnetic resonance imaging for people with multiple sclerosis. <i>Journal of Neurology</i> , 2020, 267, 2421-2431.	1.8	1
18	Assessing balance in non-disabled subjects with multiple sclerosis: Validation of the Fullerton Advanced Balance Scale. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102085.	0.9	6

#	ARTICLE	IF	CITATIONS
19	A resilience group training program for people with multiple sclerosis: Results of a pilot single-blind randomized controlled trial and nested qualitative study. PLoS ONE, 2020, 15, e0231380.	1.1	38
20	eMSQOL-29: Prospective validation of the abbreviated, electronic version of MSQOL-54. Multiple Sclerosis Journal, 2019, 25, 856-866.	1.4	11
21	Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. Frontiers in Neurology, 2019, 10, 916.	1.1	21
22	Impact of natural menopause on multiple sclerosis: a multicentre study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1201-1206.	0.9	39
23	Older age, higher perceived disability and depressive symptoms predict the amount and severity of work-related difficulties in persons with multiple sclerosis. Disability and Rehabilitation, 2019, 41, 2255-2263.	0.9	6
24	Randomized controlled trial of a home-based palliative approach for people with severe multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 663-674.	1.4	35
25	Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis. JAMA Neurology, 2018, 75, 35.	4.5	65
26	Atypical Post-Injection Reactions with Delayed Onset Following Glatiramer Acetate 40Âmg: Need for Titration?. CNS Drugs, 2018, 32, 653-660.	2.7	1
27	Participant perspectives of a home-based palliative approach for people with severe multiple sclerosis: A qualitative study. PLoS ONE, 2018, 13, e0200532.	1.1	9
28	A cloud-based platform for effective supervision of autonomous home rehabilitation through exer-games. , 2018, , .		11
29	Difficulties in adjustment to multiple sclerosis: vulnerability and unpredictability of illness in the foreground. Disability and Rehabilitation, 2017, 39, 897-903.	0.9	27
30	Managing the transition (ManTra): a resource for persons with secondary progressive multiple sclerosis and their health professionals: protocol for a mixed-methods study in Italy. BMJ Open, 2017, 7, e017254.	0.8	16
31	Cognitive function alone is a poor predictor of health-related quality of life in employed patients with MS: results from a cross-sectional study. Clinical Neuropsychologist, 2016, 30, 201-215.	1.5	7
32	Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories. Quality of Life Research, 2016, 25, 2755-2763.	1.5	10
33	Development and assessment of a website presenting evidence-based information for people with multiple sclerosis: the IN-DEEP project. BMC Neurology, 2016, 16, 30.	0.8	15
34	Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness. Journal of the Neurological Sciences, 2016, 368, 402-407.	0.3	17
35	Identification of a gene expression signature in peripheral blood of multiple sclerosis patients treated with disease-modifying therapies. Clinical Immunology, 2016, 173, 133-146.	1.4	9
36	Psychosocial difficulties of individuals with multiple sclerosis: the PARADISE-24 questionnaire. International Journal of Rehabilitation Research, 2016, 39, 339-345.	0.7	8

#	ARTICLE	IF	CITATIONS
37	Low quality of life and psychological wellbeing contrast with moderate perceived burden in carers of people with severe multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2016, 366, 139-145.	0.3	26
38	Multiple Sclerosis Questionnaire for Job Difficulties (MSQ-Job): definition of the cut-off score. <i>Neurological Sciences</i> , 2016, 37, 777-780.	0.9	2
39	A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study. <i>Journal of the Neurological Sciences</i> , 2016, 364, 105-109.	0.3	5
40	Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory. <i>PLoS ONE</i> , 2016, 11, e0153466.	1.1	31
41	Development of a shortened version of the MSQOL-54 using factor analysis and item response theory. <i>Journal of the Neurological Sciences</i> , 2015, 357, e318-e319.	0.3	1
42	Development and validation of the multiple sclerosis questionnaire for the evaluation of job difficulties (MSQ-Job). <i>Acta Neurologica Scandinavica</i> , 2015, 132, 226-234.	1.0	12
43	Patient Expression of Emotions and Neurologist Responses in First Multiple Sclerosis Consultations. <i>PLoS ONE</i> , 2015, 10, e0127734.	1.1	31
44	Home-based palliative approach for people with severe multiple sclerosis and their carers: study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 184.	0.7	28
45	Quantitative Detection of Epstein-Barr Virus DNA in Cerebrospinal Fluid and Blood Samples of Patients with Relapsing-Remitting Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e94497.	1.1	32
46	Unmet Needs of People with Severe Multiple Sclerosis and Their Carers: Qualitative Findings for a Home-Based Intervention. <i>PLoS ONE</i> , 2014, 9, e109679.	1.1	67
47	Implementation of the "Sapere Migliora"™ information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1234-1243.	1.4	14
48	Experience of an information aid for newly diagnosed multiple sclerosis patients: a qualitative study on the SIMS trial. <i>Health Expectations</i> , 2014, 17, 36-48.	1.1	12
49	Web Search Behavior and Information Needs of People With Multiple Sclerosis: Focus Group Study and Analysis of Online Postings. <i>Interactive Journal of Medical Research</i> , 2014, 3, e12.	0.6	51
50	P.12.4 Great phenotypic variability in two siblings affected by congenital myasthenic syndrome associated with mutations in MUSK. <i>Neuromuscular Disorders</i> , 2013, 23, 806.	0.3	0
51	Exacerbation of experimental autoimmune encephalomyelitis by passive transfer of IgG antibodies from a multiple sclerosis patient responsive to immunoadsorption. <i>Journal of Neuroimmunology</i> , 2013, 262, 19-26.	1.1	10
52	P.21.1 Autophagy as a link between immunity and inflammation in idiopathic inflammatory myopathies. <i>Neuromuscular Disorders</i> , 2013, 23, 843-844.	0.3	0
53	Complete stable remission and autoantibody specificity in myasthenia gravis. <i>Neurology</i> , 2013, 80, 188-195.	1.5	53
54	Factors related to difficulties with employment in patients with multiple sclerosis. <i>International Journal of Rehabilitation Research</i> , 2013, 36, 105-111.	0.7	106

#	ARTICLE	IF	CITATIONS
55	A New Thiopurine Sâ€Methyltransferase Haplotype Associated With Intolerance to Azathioprine. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 67-74.	1.0	21
56	Decision-Making in Multiple Sclerosis Consultations in Italy: Third Observer and Patient Assessments. <i>PLoS ONE</i> , 2013, 8, e60721.	1.1	44
57	Anxiety and depression in multiple sclerosis patients around diagnosis. <i>Journal of the Neurological Sciences</i> , 2011, 307, 86-91.	0.3	105
58	Human Neurotrophin Receptor p75NTR Defines Differentiation-Oriented Skeletal Muscle Precursor Cells: Implications for Muscle Regeneration. <i>Journal of Neuropathology and Experimental Neurology</i> , 2011, 70, 133-142.	0.9	26
59	Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. <i>Neurology</i> , 2011, 76, 2079-2088.	1.5	71
60	The relationship between health, disability and quality of life in Myasthenia Gravis: results from an Italian study. <i>Journal of Neurology</i> , 2010, 257, 98-102.	1.8	48
61	Concordance between severity of disease, disability and health-related quality of life in Myasthenia gravis. <i>Neurological Sciences</i> , 2010, 31, 41-45.	0.9	45
62	The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients. <i>Multiple Sclerosis Journal</i> , 2010, 16, 100-111.	1.4	50
63	An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1393-1405.	1.4	64
64	Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1237-1247.	1.4	27
65	Allergy and multiple sclerosis: a population-based case-control study. <i>Multiple Sclerosis Journal</i> , 2009, 15, 899-906.	1.4	29
66	Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests. <i>Journal of Applied Physiology</i> , 2009, 106, 1311-1324.	1.2	76
67	Identification of international classification of functioning, disability and health relevant categories to describe functioning and disability of patients with myasthenia gravis. <i>Disability and Rehabilitation</i> , 2009, 31, 2041-2046.	0.9	21
68	Disability and functional profiles of patients with myasthenia gravis measured with ICF classification. <i>International Journal of Rehabilitation Research</i> , 2009, 32, 167-172.	0.7	19
69	Immunotherapy responsive startle with antibodies to voltage gated potassium channels. <i>BMJ Case Reports</i> , 2009, 2009, bcr0920080988-bcr0920080988.	0.2	3
70	Miopatie infiammatorie. , 2009, , 539-546.		0
71	Two cases of thymoma-associated myasthenia gravis without antibodies to the acetylcholine receptor. <i>Neuromuscular Disorders</i> , 2008, 18, 678-680.	0.3	26
72	The Kinesin Superfamily Motor Protein KIF4 Is Associated With Immune Cell Activation in Idiopathic Inflammatory Myopathies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 624-632.	0.9	20

#	ARTICLE	IF	CITATIONS
73	Immunotherapy responsive startle with antibodies to voltage gated potassium channels. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1281-1290.	0.9	9
74	Novel mutations of ND genes in complex I deficiency associated with mitochondrial encephalopathy. Brain, 2007, 130, 1894-1904.	3.7	131
75	C.P.6.08 Comparison of the effects of chronic treatments with drugs targeting different disease-related pathways in dystrophic mdx mice. Neuromuscular Disorders, 2007, 17, 803.	0.3	0
76	Role of tumour necrosis factor α , but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approach. Neuropathology and Applied Neurobiology, 2007, 33, 344-359.	1.8	51
77	Excessive fragmentary hypnic myoclonus in a patient affected by a mitochondrial encephalomyopathy. Sleep Medicine, 2006, 7, 663.	0.8	14
78	First evaluation of the potential effectiveness in muscular dystrophy of a novel chimeric compound, BN 82270, acting as calpain-inhibitor and anti-oxidant. Neuromuscular Disorders, 2006, 16, 237-248.	0.3	41
79	Immunomodulation of TGF-beta1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: Implications for antifibrotic therapy. Journal of Neuroimmunology, 2006, 175, 77-86.	1.1	114
80	Overactivity of exercise-sensitive cation channels and their impaired modulation by IGF-1 in mdx native muscle fibers: Beneficial effect of pentoxifylline. Neurobiology of Disease, 2006, 24, 466-474.	2.1	40
81	A post-marketing study on immunomodulating treatments for relapsing-remitting multiple sclerosis in Lombardia: preliminary results. Neurological Sciences, 2005, 26, s171-s173.	0.9	9
82	A Multidisciplinary Evaluation of the Effectiveness of Cyclosporine A in Dystrophic Mdx Mice. American Journal of Pathology, 2005, 166, 477-489.	1.9	107
83	Response to Dr. Jaretzki's letter on video-assisted thoracoscopic extended thymectomy. Journal of the Neurological Sciences, 2004, 217, 235-236.	0.3	4
84	Letter to the editor. Journal of the Neurological Sciences, 2004, 217, 233-234.	0.3	11
85	Expression of Transforming Growth Factor- β 1 in Thymus of Myasthenia Gravis Patients. Annals of the New York Academy of Sciences, 2003, 998, 278-283.	1.8	9
86	Myasthenia Gravis (MG): Epidemiological Data and Prognostic Factors. Annals of the New York Academy of Sciences, 2003, 998, 413-423.	1.8	135
87	Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. Journal of Neuroimmunology, 2003, 142, 130-136.	1.1	126
88	Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients: remission after 6 years of follow-up. Journal of the Neurological Sciences, 2003, 212, 31-36.	0.3	126
89	Fibrogenic cytokines and extent of fibrosis in muscle of dogs with X-linked golden retriever muscular dystrophy. Neuromuscular Disorders, 2002, 12, 828-835.	0.3	51
90	Increased Expression of β 2-Chemokines in Muscle of Patients with Inflammatory Myopathies. Journal of Neuropathology and Experimental Neurology, 2000, 59, 164-169.	0.9	81

#	ARTICLE	IF	CITATIONS
91	Identification of three novel mutations in the major human skeletal muscle chloride channel gene (CLCN1), causing myotonia congenita. <i>Human Mutation</i> , 1999, 14, 447-447.	1.1	21
92	Transforming growth factor- β 1 and fibrosis in congenital muscular dystrophies. <i>Neuromuscular Disorders</i> , 1999, 9, 28-33.	0.3	122
93	A novel mutation (8342G \rightarrow A) in the mitochondrial tRNA ^{Lys} gene associated with progressive external ophthalmoplegia and myoclonus. <i>Neuromuscular Disorders</i> , 1999, 9, 66-71.	0.3	32
94	Identification of a Novel HLA Class II Association with DQB1*0502 in an Italian Myasthenic Population. <i>Annals of the New York Academy of Sciences</i> , 1998, 841, 355-359.	1.8	24
95	Anti-titin and Antiryanodine Receptor Antibodies in Myasthenia Gravis Patients with Thymoma. <i>Annals of the New York Academy of Sciences</i> , 1998, 841, 538-541.	1.8	35
96	Video-assisted Thoracoscopic Extended Thymectomy (VATET) in Myasthenia Gravis Two-Year Follow-up in 101 Patients and Comparison with the Transsternal Approach. <i>Annals of the New York Academy of Sciences</i> , 1998, 841, 749-752.	1.8	28
97	Plasma Treatment in Diseases of the Neuromuscular Junction. <i>Annals of the New York Academy of Sciences</i> , 1998, 841, 803-810.	1.8	10
98	The expression of co-stimulatory and accessory molecules on cultured human muscle cells is not dependent on stimulus by pro-inflammatory cytokines: relevance for the pathogenesis of inflammatory myopathy. <i>Journal of Neuroimmunology</i> , 1998, 85, 52-58.	1.1	22
99	Long-term selective IgG immunoadsorption improves Rasmussen's encephalitis. <i>Neurology</i> , 1998, 51, 302-305.	1.5	106
100	Transforming Growth Factor- β 1 in Polymyositis and Dermatomyositis Correlates with Fibrosis but not with Mononuclear Cell Infiltrate. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997, 56, 479-484.	0.9	57
101	Emerging Treatments in Myopathies. <i>European Neurology</i> , 1997, 38, 222-229.	0.6	3
102	Antineuronal Antibody in a Patient with Neuroblastoma and Opsoclonus-Myoclonus-Ataxia: A Case Report. <i>Tumori</i> , 1997, 83, 709-711.	0.6	8
103	Inflammatory myopathies and systemic disorders: a review of immunopathogenetic mechanisms and clinical features. <i>Journal of Neurology</i> , 1997, 244, 277-287.	1.8	52
104	Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine.. <i>Journal of Clinical Investigation</i> , 1995, 96, 1137-1144.	3.9	259
105	The POEMS syndrome: Report of six cases. <i>Italian Journal of Neurological Sciences</i> , 1994, 15, 353-358.	0.1	19
106	Changes in peripheral blood lymphocyte subset frequencies in myasthenia gravis patients are related to immunosuppression. <i>Journal of Neurology</i> , 1994, 241, 218-222.	1.8	10
107	Protein-A immunoadsorption in immunosuppression-resistant myasthenia gravis. <i>Lancet, The</i> , 1994, 343, 124.	6.3	22
108	Immune activation in myasthenia gravis: Soluble interleukin-2 receptor, interferon- β 3 and tumor necrosis factor- α levels in patients' serum. <i>Journal of Neuroimmunology</i> , 1993, 48, 33-36.	1.1	20

#	ARTICLE	IF	CITATIONS
109	Immunosuppressive Treatments: Their Efficacy on Myasthenia Gravis Patients' Outcome and on the Natural Course of the Disease. <i>Annals of the New York Academy of Sciences</i> , 1993, 681, 594-602.	1.8	28
110	A short plasma exchange protocol is effective in severe myasthenia gravis. <i>Journal of Neurology</i> , 1991, 238, 103-107.	1.8	64
111	Idiopathic Inflammatory Myopathies: A Review of Immunopathological Features and Current Models of Pathogenesis. , 0, , .		1